‘Much-needed hope’ as CRISPR gene editing therapy recommended for sickle cell disease
Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant access to gene-editing therapy on the NHS. View on euronews
NHS England to offer Casgevy for sickle cell disease patients
Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.
Sickle cell disease ‘cure’ to be offered to NHS patients
Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem cell transplant
Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England
Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to treat sickle cell disease. Read more here.
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY ® (exagamglogene autotemcel).
Vertex, U.K. reach reimbursement deal for CRISPR-based medicine for sickle cell disease
People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the U.K. and Vertex.
After inversion by CRISPR/Cas, the epigenetic state of plant chromosomes remains stable
The epigenetic state of chromatin, gene activity, and chromosomal positions are interrelated. A research team from the IPK ...
MIT Technology Review2d
Mice with two dads have been created using CRISPR
It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.
STAT8d
RFK Jr., an investor in a CRISPR biotech, has raised alarms about the technology
RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.
Crispr Therapeutics price target lowered to $30 from $45 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...
MIT Technology Review2d
The Download: mice with two dads, and Meta’s fact-checking challenges
Once a week, Sun Kai has a video call with his mother, and they discuss his day-to-day life. But Sun’s mother died five years ...
GEN7h
Next-Gen Cas12a System Enables Precise Single and Multiplexed Gene Editing in Cancer
Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.
CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...
FY2024 Earnings Estimate for CRSP Issued By Leerink Partnrs
Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...
UK health system to offer cutting-edge gene therapy for sickle cell disease
The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...
News Medical on MSN50m
Researchers create random versions of human genomes to study disease
The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more resilient to significant structural changes than was previously thought.